Drug name - Xofluza
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(8 years from now) | |
| US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(14 years from now) | |
| CN112876473A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Jun, 2022
(4 months ago) | |
| CN103228653A | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| CN103228653B | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| CN112940010B | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN113004304A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN112940010A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN113004304B | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| IN201303057P4 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| IN318238B | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| IN346800B | GENENTECH INC | Substituted Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| IN201747041390A | GENENTECH INC | Substituted Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| EP2620436A4 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| EP2620436B1 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| EP2620436A1 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| EP3428170A1 | GENENTECH INC | Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| EP3428170B1 | GENENTECH INC | Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(7 years from now) | |
| US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(8 years from now) | |
| US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
Treatment: Method for treating influenza; method for post-exposure prophylaxis of influenza
Dosage: FOR SUSPENSION;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 2MG/ML | FOR SUSPENSION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.